As Klf15 is part of the GC-GR-KLF15-BCAA pathway, previously shown to be dysregulated in SMA muscle, it is possible that mifepristone treatment in animal models or SMA patients may modulate BCAA levels. Here, KLF15 is linked to proximal spinal muscular atrophy.